Clinical Trial

First-in-Human Investigation of JMT108 Injection in Participants With Advanced Malignant Tumors

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
This study is designed as an open-label, multi-center Phase 1 clinical study in participants with advanced malignant tumors to evaluate the safety, tolerability, PK characteristics, and preliminary anti-tumor activity of JMT108 injection, and to determine the RP2D/schedule for subsequent studies.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2025-03-11; most recent amendment 2026-01-27.
Status change: Not Yet Recruiting → Recruiting 2025-04-29
Trial Details
NCT Number NCT06877650
Lead Sponsor Shanghai JMT-Bio Inc.
Conditions Advanced Malignant Tumors
Enrollment 436 participants
Start Date 2025-04-11
Primary Completion 2028-03-30 (estimated)
Study Completion 2029-03-30 (estimated)
Updated on ClinicalTrials.gov 2026-01-29